Towards personalized anti-colorectal cancer therapy by targeting cancer cell metabolism heterogeneity
SRP-Groeifinanciering: Unravelling the host-parasite interactions that result in B cell destruction during trypanosomosis and development of novel intervention strategies focusing on diagnosis and anti B cell cancer therapy
"GRACE-trial: A randomized active-controlled trial for vulvovaGinal atRophy in breAst Cancer patients on Endocrine therapy"
Benefits of elective para-aortic radiotherapy for pN1 prostate cancer using arc therapy (intensity-modulated or volumetric modulated arc therapy) : protocol for a nonrandomized phase II trial
SUCON Trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian Multicenter Phase II Randomized Trial in Her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy with Sunitinib after Objective Response to
The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients
Low-Energy Extracorporeal Shockwave Therapy as a Therapeutic Option for Patients with a Secondary Late-Stage Fibro-Lymphedema After Breast Cancer Therapy: A Pilot Study
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD databas
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
A platform for next-generation comprehensive proteome analysis: liquid chromatography trapped-ion-mobility time- of-flight (LC-timsTOF) mass spectrometry (LS-timsTOF)
Replication Data for: Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells